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Methods for the enantioselective synthesis of (+) and (—) 
lofexidine or 2-[1-(2,6)-dichlorophenoxy)-ethyl]-1,3-diaZa 
cyclopent-2-ene involve converting (+) or (—) 1-methyl-1-[2, 
6-dichlorophenoxy]ethanamide to an (+) or (—) imino -ether 
intermediate by electrophilic attack of the amide oxygen by a 
trimethoxonium ion and, Without isolation, converting the (+) 
or (—) imino-ether intermediate to (+) or (—) 2-[1-(2,6-dichlo 
rophenoxy)-ethyl]1,3-diaZacyclopent-2-ene by adding ethyl 
ene diamine; and optionally converting the (+) or (—) 2-[1-(2, 
6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene into a 
pharrnaceutically acceptable acid addition salt thereof. 
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ENANTIOSELECTIVE SYNTHESIS OF (+) 
AND 
(—)-2-[1-(2,6-DICHLOROPHENOXY)-ETHYL] 
1,3-DIAZACYCLOPENT-2-ENE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority under 35 U.S.C. §119 to 
Us. Provisional Application No. 61/195,309, ?led on Oct. 6, 
2008, the entire content of Which is hereby incorporated by 
reference in its entirety. 
TECHNICAL FIELD 
This application provides a method for the enantio selective 
synthesis of (+) and (—) lofexidine or 2-[1-(2,6)-dichlorophe 
noXy)-ethyl]-1,3 -diaZacyclopent-2 -ene. 
BACKGROUND OF THE INVENTION 
(:)-lofexidine (1), an imidaZoline With (x2-adrenergic ago 
nist properties is clinically utiliZed for the purpose of amelio 
rating symptoms of disorders that stem from abberations in 
the (x2-adrenoreceptor function. For example, (:)-lofexidine 
has been used as an anti-hypertensive and for treating the 
physical and psychological symptoms of opiate abstinence in 
opiate-addicts (Wilkins, et al., Clin. Pharmacol. Ther’. 1981, 
30, 752-757; andAkhurst, Pharmacoepidemiology andDrug 
Safety 2000, 9, 43-47). 
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The pharmacological properties of (:)-lofexidine are evi 
dent upon the interaction of lofexidine either With (x2 adren 
ergic receptors or With any other macromolecule. These phar 
macological properties are the result of the individual 
properties of its tWo enantiomeric forms, (+)-lofexidine (2) 
and (—)-lofexidine (3). These chemically distinct entities dif 
fer in their a?inities toWard (x2-adrenergic receptors. (—) 
lofexidine shoWs about a 10-fold higher a?inity than that of 
(+)-lofexidine When both are individually pitted against the 
knoWn (x2-adrenergic ligand, 3 [H]-clonidine, for competitive 
displacement from the receptor. This difference betWeen (+) 
lofexidine and (—)-lofexidine is mirrored in their unequal 
capacity to loWer mean arterial blood pressure; the effect of 
(+)-lofexidine is apparent at doses as loW as 561 ng/kg, While 
that of (—)-lofexidine is not seen even at doses as high as 10 
ug/kg (Wilffer‘t, et al., Arch. Int. de. Pharmcodynamie el de 
The}: 1985, 273, 18-32). (:)-lofexidine is useful in the treat 
ment of hypertension, as Well as in the treatment of With 
draWal symptoms in opiate addicts. Accordingly, the enanti 
oselective synthesis and usage of solely (—)-lofexidine has 
been attempted. Three distinct approaches toWard the synthe 
sis of (—)-lofexidine are Well knoWn, and are described beloW. 
Optical resolution of (:)-lofexidine into (+)-lofexidine and 
(—)-lofexidine. In the Work of Biedermann et. al., (+) and 
(—)-dibenZoyl tartaric acids are reacted With (:)-lofexidine 
and subsequently alloWed to crystallize from acetone (Bied 
ermann et al., J. Med. Chem. 1986, 29, 1183-1188). After a 
total of 4 recrystalliZations, optically pure (+)-lofexidine is 
obtained (Where (+)-tartaric acid is employed) and (—)-lofexi 
dine is obtained (Where (—)-tartaric acid is employed). HoW 
ever, the overall yield of this resolution process is typically 
5-10%, making this methodology impractical for large scale 
preparation. 
Enantioselective approach toWard (+)-lofexidine and (—) 
lofexidine based on amide dehydration, nitrile alcoholysis 
and imidaZoline formation: Another approach described in 
the Work of Biedermann et. al. employs chirally pure ethyl 
lactate as a starting material. The synthesis (Scheme 1) 
involves a tWo-step inversion of the ot-chiral center of ethyl 
lactate folloWed by amidation, dehydration of the amide, 
alcoholysis of the resulting nitrile and conversion of the 
resulting imino-ether into imidaZoline folloWed by sali?ca 
tion by anhydrous HCl. An overall yield of 5% is obtained 
after 8 synthetic transformations that employ tWo high 
vacuum distillation processes. 
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Enantioselective approach toward (+)-lofexidine and (—) 
lofexidine based on Lewis-acid mediated imidaZoline forma 
tion: US. Pat. No. 4,518,783 is directed to a synthetic route 
toward chirally pure lofexidine (Scheme 2) that begins from 
intermediate 6 of scheme 1.Amidati0n with ethylene diamine 
is followed by Lewis-acid mediated cycliZation to imidaZo 
line. An overall yield of 4% is obtained over 5 synthetic 
transformations that involve a silica-gel column chromatog 
raphy process following the Lewis-acid mediated imidaZo 
line formation. 
Scheme 2. Lewis-acid mediated imidazoline formation. 
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The synthesis of a related imidaZoline; m-nitrobiphe 
nyline, is also known. (Crassous et al., J. Med. Chem. 2007, 
50, 3964-3968). Shown in Scheme 3, a Mitsonubu inversion 
of the ot-hydroxy function of methyl lactate yields an analog 
of 6. The resulting substituted methyl ester 20 is converted to 
an imidaZoline by heating it with ethylene diamine in dry 
toluene in the presence of AlCl3. This approach fails to yield 
a chirally pure product, as the enantiomeric excess was found 
to be 72%. 
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Scheme 3. AlCl3—rnediated imidazoline formation in the synthesis of m 
nitrobiphenylene. 
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Thus, new methods for synthesizing (+) and (—) lofexidine 
are needed, which provide greater yields than the processes 
known in the art, and which improve the ease and improves 
the overall ease and yields of the process, without harm to the 
stereochemical integrity of the product. 
SUMMARY OF THE INVENTION 
This invention relates to the chemical transformation of 
chirally pure methyl lactate to yield chirally pure (+)-lofexi 
dine or (—)-lofexidine with better yield than known methods, 
and without the usage of additional puri?cation techniques, 
such as distillation or chromatography. 
One aspect of the present invention provides an enantiose 
lective synthesis of (+) or (—) 2-[1-(2,6-dichlorophenoxy) 
ethyl] 1 ,3-diaZacyclopent-2-ene (lofexidine) or a pharmaceu 
tically acceptable acid addition salt thereof comprising: 
converting (+) or (—) 1 -methyl-1-[2,6-dichlorophenoxy]etha 
namide to the (+) or (—) imino-ether intermediate by electro 
philic attack of the amide oxygen by a trimethoxonium ion 
and, without isolation, converting the (+) or (—) imino-ether 
intermediate to (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl] 
1,3-diaZacyclopent-2-ene by adding ethylene diamine. 
Optionally, (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3 
diaZacyclopent-2-ene may be converted into a pharmaceuti 
cally acceptable acid addition salt thereof. 
Another aspect of the present invention provides an enan 
tioselective synthesis of (+) or (—) 2-[1-(2,6-dichlorophe 
noxy)-ethyl]1,3-diaZacyclopent-2-ene or a pharmaceutically 
acceptable acid addition salt thereof comprising: (a) convert 
ing (+) or (—) 1-methyl-1-hydroxyethanoate to (+) or (—) 
1-methyl-1-[2,6-dichlorophenoxy]ethanoate by reacting 
with 2, 6-dichlorophenol, triphenylphosphine and diisopropyl 
aZodicarboxylate; (b) converting the (+) or (—) 1-methyl-1 
[2,6-dichlorophenoxy]ethanoate to (+) or (—) 1-methyl-1-[2, 
6-dichlorophenoxy]ethanamide; (c) converting (+) or (—) 
1-methyl-1-[2,6-dichlorophenoxy]ethanamide to (+) or (—) 
imino-ether intermediate by electrophilic attack of the amide 
oxygen by a trimethoxonium ion and, without isolation, con 
verting the (+) or (—) imino-ether intermediate to (+) or (—) 
2-[1-(2,6-dichlorophenoxy)-ethyl]1,3 -diaZacyclopent-2-ene 
by adding ethylene diamine; and (d) optionally converting the 
(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo 
pent-2-ene into a pharmaceutically acceptable acid addition 
salt thereof. 
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DETAILED DESCRIPTION OF THE INVENTION 
De?nitions and Abbreviations 
In accordance With this detailed description, the following 
abbreviations and de?nitions apply. It must be noted that as 
used herein, the singular forms “a”, “an”, and “the” include 
plural referents unless the context clearly dictates otherWise. 
Thus, for example, reference to “an antibody” includes a 
plurality of such antibodies and reference to “the dosage” 
includes reference to one or more dosages and equivalents 
thereof knoWn to those skilled in the art, and so forth. 
The publications discussed herein are provided solely for 
their disclosure prior to the ?ling date of the present applica 
tion. Nothing herein is to be construed as an admission that 
the present invention is not entitled to antedate such publica 
tion by virtue of prior invention. Further, the dates of publi 
cation provided may be different from the actual publication 
dates, Which may need to be independently con?rmed. 
By the term “subject” or “patient” as used herein is meant 
to include a mammal. The mammal can be a canine, feline, 
primate, bovine, ovine, porcine, camelid, caprine, rodent, or 
equine. Preferably the mammal is human. 
By the term “optionally” is meant that the step or action is 
not required or mandatory, but may or may not be performed. 
The folloWing abbreviations are used herein: 
AlCl3 aluminum chloride 
CDCl3 deuterated chloroform 
CHZCl2 dichloromethane 
DIAD diisopropyl azodicarboxylate 
EtOH ethanol 
HCl hydrochloric acid 
i-PrOH isopropyl alcohol 
K2CO3 potassium carbonate 
Na2SO4 sodium sulfate 
NMR nuclear magnetic resonance 
Ph3P triphenylphosphine 
The present invention provides the ?rst instance of an 
enantioselective synthesis of lofexidine that proceeds in 
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meaningful overall yields and does not require additional 
puri?cation techniques, such as distillation or column chro 
matography. 
While all previous procedures have utiliZed a tWo-step 
amide-dehydration and nitrile alcoholysis to generate an 
imino-ether intermediate, the present method involves a one 
step conversion. The present methods utiliZe a direct electro 
philic attack of the amide oxygen by a trimethoxonium ion. 
This transformation greatly improves the overall ease and 
yield of the process, Without harm to the stereochemical 
integrity of the con?guration about the ot-carbon. 
The present synthesis scheme provides chirally pure 
lofexidine With greater yields than schemes knoWn in the art. 
In one embodiment, the enantioselective syntheses of the 
present invention provide an overall yield of chirally pure 
lofexidine or a pharmaceutically acceptable acid addition salt 
thereof of at least 50%. In another embodiment, the enanti 
oselective syntheses of the present invention provide an over 
all yield of chirally pure lofexidine or a pharmaceutically 
acceptable acid addition salt thereof of at least 60%. In a 
speci?c embodiment, the overall yield of chirally pure lofexi 
dine, or a pharmaceutically acceptable acid addition salt 
thereof, is at least 64%. 
The present invention provides an enantio selective synthe 
sis of (+) or (—) lofexidine or a pharmaceutically acceptable 
acid addition salt thereof Which comprises converting (+) or 
(—) l—methyl-l-[2,6-dichlorophenoxy]ethanamide to the (+) 
or (—) imino-ether intermediate by electrophilic attack of the 
amide oxygen by a trimethoxonium ion. Then, Without iso 
lation, the (+) or (—) imino-ether intermediate is converted to 
(+) or (—) lofexidine by adding ethylene diamine. The (+) or 
(—) lofexidine can be converted into a pharmaceutically 
acceptable acid addition salt if desired. The syntheses of the 
present invention are described in detail beloW. 
Commercially available (+) or (—) methyl lactate (22 or 23) 
(for example, obtained from Sigma Aldrich) may serve as 
starting materials in the present synthesis. The synthesis of 
(—)-lofexidine (3), beginning from 22 is illustrated and 
described beloW. 
Scheme 4. Synthesis of — —lofexidine 3 . 
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? C1 C1 
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o o 0 
D1 AD from EtOH 
23 0° c. to $411 24 25 
C1 
+ _ I I O 1- Me3O BF4 CHZClZ, 36 h crystallization Cl 
2. HZNCHZCHZNH, EtOH, 00 C. to it from hexanes OCH3 
85% (one pot) 
NH2+BF4' 
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The starting material, commercially available (+) or (—) 
methyl lactate ((+) or (—) 1-methyl-1-hydroxyethanoate), is 
reacted With 2,6-dichlorophenol, triphenylphosphine (Ph3P) 
and diisopropyl azodicarboxylate (DIAD) to provide (+) or 
(—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate. In one 
embodiment, the reaction takes place in a solvent that dis 
solves the (+) or (—) 1-methyl-1-hydroxyethanoate, 2,6 
dichlorophenol, triphenylphosphine and diisopropyl azodi 
carboxylate and precipitates triphenylphosphine oxide. The 
solvent can consist of an approximately 1:1 ratio of a polor 
aprotic solvent and a nonpolar solvent. In one embodiment, 
the polor aprotic solvent is ether, and the nonpolar solvent is 
hexanes. In one embodiment, the (+) or (—) 1-methyl-1-hy 
droxyethanoate is reacted With 2,6-dichlorophenol, triph 
enylphosphine and diisopropyl azodicarboxylate at approxi 
mately 0° C. and then alloWed to Warm to approximately 
room temperature. 
For example, methyl ester 22 is reacted With 2,6-dichlo 
rophenol, triphenylphosphine and diisopropyl azodicarboxy 
late in a solvent consisting of ether and hexanes in a 1:1 ratio 
at 0° C. and the reaction mixture is alloWed to Warm to room 
temperature over a period of four hours. This particular sol 
vent combination alloWs for complete dissolution of all start 
ing materials and initiation of the precipitation of triph 
enylphosphine oxide from the reaction mixture. The 
utilization of anhydrous grades of these solvents during the 
preparation of 24 is not necessary, in contrast to What gener 
ally is used for this type of transformation. After completion 
of the reaction (about 4 hours), the precipitation of triph 
enylphosphine is completed by dilution of the reaction mix 
ture With heptane to tWice its volume. After ?ltration, the 
?ltrate is evaporated to an amber oil (crude 24) Which is 
subjected to the next step Without any further puri?cation, in 
this speci?c example. 
Next, the (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy] 
ethanoate is converted to (+) or (—) 1-methyl-1-[2,6-dichlo 
rophenoxy]ethanamide. Conversion of the ether to the amide 
can be accomplished by treatment With ammonia. In one 
embodiment, the (+) or (—) 1-methyl-1-[2,6-dichlorophe 
noxy]ethanoate is converted to the amide by treatment With a 
solution of ammonia in an alcohol. For example, crude 24 is 
treated With a solution of ammonia in absolute ethanol for 12 
hours to provide partial crystallization of the product 25 from 
the reaction mixture. The reaction is then re?uxed to drive off 
excess ammonia and diluted With boiling ethanol to dissolve 
the entirety of the solid mass. Undissolved solids are then 
?ltered to provide a clear, pale yelloW ?ltrate that yields large 
needles of pure 25 upon cooling to 0° C. 
Then, the (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy] 
ethanamide is converted to (+) or (—) imino-ether intermedi 
ate by electrophilic attack of the amide oxygen by a tri 
methoxonium ion and, Without isolation, converting the (+) or 
(—) imino-ether intermediate to (+) or (—) 2-[1-(2,6-dichlo 
rophenoxy)-ethyl]1,3-diazacyclopent-2-ene by adding ethyl 
ene diamine. In one embodiment, the trimethoxonium ion is 
trimethyloxonium tetra?uoroborate. In one embodiment, 
approximately 1.1 equivalents ethylene diamine are added as 
an alcohol solution. 
For example, pure 25 obtained above is dissolved in 
reagent-grade CH2Cl2 and treated With an equivalent of tri 
methyloxonium tetra?uoroborate. The suspension becomes a 
clear solution upon stirring for 36 hours at room temperature. 
This solution, containing an imino-ether intermediate, is 
cooled to 0° C. and 1.1 equivalents of ethylene diamine are 
added as a 10% solution in absolute ethanol. Upon Warming 
to room temperature, the turbid mixture is evaporated to 
dryness and partitioned between CH2Cl2 and 5% aqueous 
K2CO3. The organic layer is dried and then evaporated, Which 
provides a solid residue that yields (—)-lofexidine (3) as a 
mass of ?ne White needles When crystallized from hexanes. 
This material is chemically and optically pure, as judged from 
its NMR spectra and optical rotation values. 
The resulting (+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl] 
1,3-diazacyclopent-2-ene (lofexidine) product can be con 
verted into a pharmaceutically acceptable acid addition salt 
thereof if desired. For example, to provide the HCl salt, the 
crystalline material (3) is dissolved in a 4:1 mixture of ether 
and i-PrOH and is treated With 1.2 equiv. of aqueous conc. 
HCl. This results in precipitation of very ?ne colorless 
needles that are recovered by ?ltration and dried in air. 
The present invention’s conversion to the HCl salt advan 
tageously uses aqueous HCl rather than anhydrous HCl as 
taught in the literature. The use of the 4:1 mixture of ether and 
i-PrOH and With 1.2 equiv. of aqueous conc. HCl alloWs for 
the precipitation of a microcrystalline hydrochloride salt of 3, 
compound 26. The solvents and their ratios are tailored to 
achieve this precipitation. The use of anhydrous HCl in 
i-PrOH, as knoWn in the literature, is tedious to use on large 
scales and generally produces a voluminous precipitate of the 
salt. 
Compound 2, the enantiomer of (+)-lofexidine (2) and its 
hydrochloride salt may be obtained in a similar fashion, start 
ing With the (+)-methyl lactate (23). 
Although the present invention has been described in detail 
With reference to the example beloW, it is understood that 
various modi?cations can be made Without departing from 
the spirit of the invention, and Would be readily knoWn to the 
skilled artisan. 
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EXAMPLE 
(—)-2-(2,6-dichlorophenoxy)-propionamide (25). To 1-L 
round bottom ?ask equipped With a stir-bar Were added (+) 
methyl lactate (25.00 g, 240.26 mmol), Ph3P (63.00 g, 241 
mmol), and 2,6-dichlorophenol (39.16 g, 240.26 mmol) and 
ether-hexanes (1:1, 250 mL). After cooling to 0° C., DIAD 
(49.00 g, 241 mmol) Was added dropWise over 30 minutes and 
the resulting yelloW solution Was Warmed to room tempera 
ture over a period of 4 hours, during Which, ?ne White needles 
of triphenyl phosphine oxide crystallized. The mixture Was 
diluted With 250 mL of heptanes, stirred for 30 minutes and 
60 
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?ltered through a Buchner funnel. The ?lter cake Was Washed 
With heptane (100 mL, 2x) and the ?ltrates Were evaporated to 
an amber oil containing 24, that Was directly subjected to the 
next transformation Without any further puri?cation. 
The amber oil obtained above (65 g crude) Was dissolved in 
500 mL absolute EtOH and cooled to 0° C. Ammonia gas Was 
passed through this solution until the solution Was judged to 
be saturated (seen as greatly increased bubbling of gas). The 
mixture Was alloWed to Warm to room temperature (unstirred) 
over 12 h, folloWing Which, it Was re?uxed for 15 min. and 
diluted With EtOH (250 mL) and re?uxed for 30 min. This 
mixture Was ?ltered hot and the ?ltrate Was cooled in the 
refrigerator for 2 h Which led to the formation of a mass of 
White needles, that Was removed by ?ltration and dried in air 
for 30 min to yield 25 (50.00 g, 89%). 1H NMR (300 MHZ, 
CDCl3) 6 ppm 7.35-7.25 (m, 2H, Ar), 7.03 (t, J:8.4 HZ, 1H, 
Ar), 6.93 (br, s, NH), 6.08 (br, s, NH), 4.93 (q, 1H, 1:69 HZ), 
1.50 (d, 3H, 1:69 HZ); 13C NMR (75 MHZ, CDCl3) 6 ppm 
174.2, 148.9, 129.7, 129.4, 125.7, 79.3, 18.1; mp:192-193o 
C. (EtOH); [0t]23D:—18.9° (c 1.0, EtOH) (lit.4 [0t]2OD:—20. 1 ° 
(c 1.0, acetone). 
(—)-2- [1 -(2, 6-dichlorophenoxy) -ethyl] -1 ,3 -diaZacyclo 
pent-2-ene (3). A mixture of 25 (25 g, 106.8 mmol), trimethy 
loxonium tetra?uoroborate (16.6 g, 110 mmol) and CH2Cl2 
(600 mL) Was stirred for 36 hours, during Which the coarse 
suspension changed to a clear, colorless solution. Cooling of 
this solution of 00 C. Was folloWed by a dropWise addition of 
ethylene diamine (7.00 g, 1.1 equiv) over 10 minutes. The 
resulting solution Was Warmed to room temperature, diluted 
With absolute ethanol (200 mL) and then evaporated to dry 
ness. The pasty White residue Was partitioned betWeen 5% 
aqueous KZCO3 (200 mL) and CH2Cl2 (500 mL). The organic 
layer Was dried (N a2SO4) and evaporated under reduced pres 
sure. Recrystallization of the residue from boiling hexanes 
(500 mL) afforded pure 3 as White needles that Were removed 
by ?ltration and dried in air (23.52 g, 85%). 1H NMR (300 
MHZ, d6-DMSO) 6 ppm 7.46-7.44 (m, 2H, Ar), 7.14 (t, J:7.8 
HZ, 1H, Ar), 6.45 (s, 1H, NH), 4.79 (q, 1:66 HZ, 1H), 3.43 
3.37 (s, br, 4H), 1.47 (d, 1:66 HZ, 3H). 13C NMR (75 MHZ, 
d6-DMSO) 6 ppm 166.3, 150.0, 130.0, 129.6, 129.5, 129.2, 
126.6, 77.3, 50.4 (very broad), 19.2; mp:129-130o C. (hex 
anes); [0t]23D:—80.2° (c 1.0, EtOH) (lit.4 [(X]2OD:—76.4o (c 
1.0, EtOH). 
(—)-2- [1 -(2, 6-dichlorophenoxy) -ethyl] -1 ,3 -diaZacyclo 
pent-2-ene hydrochloride (26). To a solution of 3 (10.00 g, 39 
mmol) in 4:1 ether/i-PrOH (100 mL) Was added dropWise 
conc. aqueous HCl (3.5 mL, 1.1 equiv.). Upon stirring for 10 
minutes the suspension Was diluted With ether (100 mL), 
?ltered and the ?lter-cake Was Washed With ether (3><50 mL) 
and air-dried, affording 26 (11.40 g, 100%). 1H NMR (300 
MHZ, d6-DMSO) 6 ppm 10.86 (s, 2H, NH), 7.52 (d, J:8.1 HZ, 
2H, Ar), 7.23 (t, J:8.1 HZ, 1H, Ar), 5.20 (q, 1:66 HZ, 1H) 
3.87 (s, br, 4H), 1.66 (d, 1:66 HZ, 3H); 13C NMR (75 MHZ, 
d6-DMSO) 6 ppm 169.5, 149.2, 130.3, 129.1, 127.5, 73.9, 
45.2, 19.5; mp:226-227o C.; [0t]23D:—39.0° (c 1.0, EtOH) 
(lit.5 [0t]2OD —34.5° (c 1.0, EtOH). 
All references cited above are incorporated herein in their 
entirety for all purposes. 
That Which is claimed: 
1. An enantioselective synthesis of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof compris 
1ng: 
converting (+) or (—) 1—methyl-1-[2,6-dichlorophenoxy] 
ethanamide to an (+) or (—) imino-ether intermediate by 
electrophilic attack of the amide oxygen by a tri 
methoxonium ion and, Without isolation, converting the 
(+) or (—) imino-ether intermediate to (+) or (—) 2-[1-(2, 
6-dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2-ene by 
adding ethylene diamine; and optionally converting the 
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(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZa 
cyclopent-2-ene into a pharmaceutically acceptable acid 
addition salt thereof. 
2. The enantioselective synthesis of claim 1 Wherein the 
trimethoxonium ion is trimethyloxonium tetra?uoroborate. 
3. The enantioselective synthesis of claim 1 Wherein 
approximately 1.1 equivalents ethylene diamine are added as 
an alcohol solution. 
4. The enantioselective synthesis of claim 1 Wherein the (+) 
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent 
2-ene is crystalliZed from hexanes. 
5. The enantioselective synthesis of claim 1 Wherein the (+) 
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent 
2-ene is converted into a HCl salt by dissolving and treating 
With aqueous concentrated HCl. 
6. The enantioselective synthesis of claim 5 Wherein the (+) 
or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclopent 
2-ene is converted into a HCl salt by dissolving in an approxi 
mately 4: 1 mixture of ether and isopropyl alcohol and treating 
With aqueous concentrated HCl to precipitate a microcrystal 
line hydrochloride salt of (+) or (—) 2-[1-(2,6-dichlorophe 
noxy)-ethyl] 1,3 -diaZacyclopent-2-ene. 
7. The enantioselective synthesis of claim 1, Wherein the 
synthesis provides an overall yield of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof of at least 
50%. 
8. The enantioselective synthesis of claim 1, Wherein the 
synthesis provides an overall yield of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof of at least 
60%. 
9. An enantioselective synthesis of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof compris 
ing: 
(a) converting (+) or (—) 1—methyl-1—hydroxyethanoate to 
(+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate 
by reacting With 2,6-dichlorophenol, triphenylphos 
phine and diisopropyl aZodicarboxylate; 
(b) converting the (+) or (—) 1-methyl-1-[2,6-dichlorophe 
noxy]ethanoate to (+) or (—) 1-methyl-1-[2,6-dichlo 
rophenoxy]ethanamide; 
(c) converting (+) or (—) 1-methyl-1-[2,6-dichlorophe 
noxy]ethanamide to (+) or (—) imino-ether intermediate 
by electrophilic attack of the amide oxygen by a tri 
methoxonium ion and Without isolation converting the 
(+) or (—) imino-ether intermediate to (+) or (—) 2-[1-(2, 
6-dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2-ene by 
adding ethylene diamine; and 
(d) optionally converting the (+) or (—) 2-[1-(2,6-dichlo 
rophenoxy)-ethyl] 1 ,3 -diaZacyclopent-2-ene into a phar 
maceutically acceptable acid addition salt thereof. 
10. The enantioselective synthesis of claim 9 Wherein step 
(a) is performed in a solvent that dissolves the (+) or (—) 
1—methyl-1—hydroxyethanoate, 2,6-dichlorophenol, triph 
enylphosphine and diisopropyl aZodicarboxylate and precipi 
tates triphenylphosphine oxide. 
11. The enantioselective synthesis of claim 9 Wherein step 
(a) is performed in a solvent consisting of an approximately 
1:1 ratio of a polor aprotic solvent and a nonpolar solvent. 
12. The enantioselective synthesis of claim 9 Wherein step 
(a) is performed in a solvent consisting of an approximately 
1:1 ratio of ether and hexanes. 
13. The enantioselective synthesis of claim 9 Wherein in 
step (a) the (+) or (—) 1-methyl-1—hydroxyethanoate is reacted 
With 2, 6-dichlorophenol, triphenylphosphine and diisopropyl 
aZodicarboxylate at approximately 00 C. and alloWed to Warm 
to approximately room temperature. 
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14. The enantioselective synthesis of claim 9 wherein the 
(+) or (—) 1-methyl-1-[2,6-dichlorophenoxy]ethanoate is 
converted to (+) or (—) 1-methyl-1-[2,6-dichlorophenoxy] 
ethanamide by treatment of a solution of ammonia in an 
alcohol. 
15. The enantioselective synthesis of claim 9 Wherein the 
trimethoxonium ion is trimethyloxonium tetra?uoroborate. 
16. The enantioselective synthesis of claim 9 Wherein in 
step (c) approximately 1.1 equivalents ethylene diamine are 
added as an alcohol solution. 
17. The enantioselective synthesis of claim 9 Wherein the 
(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo 
pent-2-ene is crystallized from hexanes. 
18. The enantioselective synthesis of claim 9 Wherein the 
(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo 
pent-2-ene is converted into a HCl salt by dissolving and 
treating With aqueous concentrated HCl. 
19. The enantioselective synthesis of claim 18 Wherein the 
(+) or (—) 2-[1-(2,6-dichlorophenoxy)-ethyl]1,3-diaZacyclo 
15 
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pent-2-ene is converted into a HCl salt by dissolving in an 
approximately 4: 1 mixture of ether and isopropyl alcohol and 
treating With aqueous concentrated HCl to precipitate a 
microcrystalline hydrochloride salt of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl] 1,3-diaZacyclopent-2 -ene. 
20. The enantioselective synthesis of claim 9, Wherein the 
synthesis provides an overall yield of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof of at least 
50%. 
21. The enantioselective synthesis of claim 9, Wherein the 
synthesis provides an overall yield of (+) or (—) 2-[1-(2,6 
dichlorophenoxy)-ethyl]1,3-diaZacyclopent-2-ene or a phar 
maceutically acceptable acid addition salt thereof of at least 
60%. 
